jrb006

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Room 623
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
  2. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
  3. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells
  4. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy
  5. Delivery of Therapeutics Targeting the mRNA Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
  6. The landscape of pancreatic cancer therapeutic resistance mechanisms
  7. Personalized therapy for Pancreatic Cancer: Do we need better targets, arrows, or both?
  8. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
  9. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis
  10. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells
  11. Current standards and novel treatment options for metastatic pancreatic adenocarcinoma
  12. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma
  13. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  14. Cancer of the pancreas
  15. Novel targets in pancreatic cancer research
  16. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
  17. Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: Native ribonucleoprotein immunoprecipitation (RIP) assays
  18. MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer
  19. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells
  20. Upgrading gemcitabine with recycled kinase inhibitors